JP2009543044A - Hccr−1を含む乳癌予後マーカー及び肥満誘導組成物 - Google Patents
Hccr−1を含む乳癌予後マーカー及び肥満誘導組成物 Download PDFInfo
- Publication number
- JP2009543044A JP2009543044A JP2009517999A JP2009517999A JP2009543044A JP 2009543044 A JP2009543044 A JP 2009543044A JP 2009517999 A JP2009517999 A JP 2009517999A JP 2009517999 A JP2009517999 A JP 2009517999A JP 2009543044 A JP2009543044 A JP 2009543044A
- Authority
- JP
- Japan
- Prior art keywords
- hccr
- apoe
- cells
- breast cancer
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000956778 Homo sapiens LETM1 domain-containing protein 1 Proteins 0.000 title claims abstract description 101
- 102100038448 LETM1 domain-containing protein 1 Human genes 0.000 title claims abstract description 101
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 47
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 43
- 208000008589 Obesity Diseases 0.000 title claims abstract description 23
- 235000020824 obesity Nutrition 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title claims abstract description 15
- 239000003550 marker Substances 0.000 title claims abstract description 12
- 230000001939 inductive effect Effects 0.000 title claims abstract description 8
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 19
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 19
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 5
- 230000009261 transgenic effect Effects 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 2
- 241000283707 Capra Species 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 241000700159 Rattus Species 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 85
- 102000013918 Apolipoproteins E Human genes 0.000 description 85
- 210000004027 cell Anatomy 0.000 description 78
- 210000001519 tissue Anatomy 0.000 description 31
- 230000014509 gene expression Effects 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 24
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 18
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 17
- 238000010186 staining Methods 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 12
- 238000013116 obese mouse model Methods 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 11
- 230000028327 secretion Effects 0.000 description 10
- 108010060159 Apolipoprotein E4 Proteins 0.000 description 9
- 241000699660 Mus musculus Species 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000011830 transgenic mouse model Methods 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 238000000636 Northern blotting Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 238000003118 sandwich ELISA Methods 0.000 description 6
- 238000008157 ELISA kit Methods 0.000 description 5
- 102000016267 Leptin Human genes 0.000 description 5
- 108010092277 Leptin Proteins 0.000 description 5
- 238000012744 immunostaining Methods 0.000 description 5
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 5
- 229940039781 leptin Drugs 0.000 description 5
- 238000000520 microinjection Methods 0.000 description 5
- 230000002438 mitochondrial effect Effects 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 210000004303 peritoneum Anatomy 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000008214 LDL Cholesterol Methods 0.000 description 3
- 239000012097 Lipofectamine 2000 Substances 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 3
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 3
- 210000004153 islets of langerhan Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000001086 yeast two-hybrid system Methods 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 102000012290 Voltage-Dependent Anion Channel 1 Human genes 0.000 description 2
- 108010022133 Voltage-Dependent Anion Channel 1 Proteins 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000030570 cellular localization Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000000749 co-immunoprecipitation Methods 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000009422 growth inhibiting effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- FZTMEYOUQQFBJR-UHFFFAOYSA-M mitoTracker Orange Chemical compound [Cl-].C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC=C(CCl)C=C1 FZTMEYOUQQFBJR-UHFFFAOYSA-M 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010070070 Hypoinsulinaemia Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001337451 Polyblastus cancer Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000011043 electrofiltration Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000033066 hyperinsulinemic hypoglycemia Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000035860 hypoinsulinemia Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000025608 mitochondrion localization Effects 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000009790 vascular invasion Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
ヒト正常組織及び癌組織は手術中に得た。すべての患者の個別同意を受けた。組織サンプルの使用は、病院の倫理委員会から承認を受けた。哺乳類細胞株はAmerican Type Culture Collection(ATCC;Manassas、VA)から得た。BT−474、MCF−7及びMDA−MB−231は、有線由来ヒト乳癌細胞株である。MCF−7及びMDA−MB−231細胞は低HER2を発現し、BT−474細胞は高HER2を発現する。BT−474及びMCF−7細胞はER−ポジティブであり、PR−ポジティブ細胞である。MDA−MB−231はER−ネガティブであり、PR−ネガティブ細胞株である。MCF−7細胞は野生型p53を有し、MDA−MB−231細胞はヌルタイプp53を有する。BT−474細胞は突然変異されたp53を有する。
HCCR−1またはApoEのコード領域を含む発現ベクターは次の通り設計された。
MATCHMAKER LexAツーハイブリッドシステムをHCCR−1融合タンパク質に結合できるヒト皮脱脳MATCHMAKER cDNAライブラリー(Clontech、Palo Alto、CA)からタンパク質を同定するために用いた。すべての実験はレポーターでlacZ及びleu遺伝子を発現するp8op−lacZに形質転換された酵母菌株EGY48(Clontech)で行った。本発明者らはLexA DNA−結合ドメインを含む酵母ツーハイブリッドベクター(pLexA)(Clontech)にHCCR−1 cDNA切片を挿入した。LexA−HCCR−1を発現する酵母細胞はB42AD融合タンパク質を発現するヒト胎児脳cDNAライブラリー(Invitrogen)に形質転換した。ライブラリー形質転換後の細胞を、AD融合タンパク質の検出機会を改良するために、ベイト(HCCR−1)及びAD/ライブラリープラスミド全てに対して選択する最小合成ドロップアウトナンインダクション培地(シグマ)にプレートした。HCCR−1と結合タンパク質ApoEとの間の相互作用を確認するために、HCCR−1とApoEを発現するプラスミドを酵母細胞に同時に形質転換した。
HCCR−1−V5−His(Invitrogen)融合タンパク質及びApoE−Myc−His(Invitrogen)をコードするpcDNA3.1(Invitrogen、Carlsbad、CA)で細胞をトランスフェクションさせた。48時間後、その細胞を集めて溶解バッファーでライシスした。その溶解液を30分間免疫前血清(マウス)及び4℃のタンパク質A−セファロスで予め浄化した。タンパク質濃度は、BCAタンパク質分析試薬キット(PIERCE、Rockford、IL)により標準の牛血清アルブミンを使用して決定した。 予め浄化された細胞破砕液アリコート(1mg)を1:500希釈液の抗−V5(Invitrogen)または1:250希釈液の抗−Myc(Invitrogen)mAb及び40mlの1:1タンパク質A−セファロースビーズスラリ(Amersham Biosciences、Uppsala、Sweden)で4℃のPBSで16時間培養した。免疫複合体を遠心分離(2,000×g、5min、4℃)で集め、バッファー(20mM Tris、pH7.5、1mM EDTA、1mM EGTA、150mM NaCl、2mM Na3VO4、10%のグリセロール及び1%のNonidet P−40)で4回洗浄し、SDS−PAGEを行い、TBSで1:1000希釈液の抗−Mycまたは1:3000希釈液の抗−V5抗体でウェスタンブロットを行った。
細胞内局在決定をミトコンドリア分離キット(Pierce、Rockford、IL)によって行った。簡単に要約すると、細胞を850×gで2分間遠心分離して収集し、そのペレットを800μl試薬Aで浮遊させた後、正確に2分間氷で維持させた。10μlの試薬Bを前記浮遊液に添加し、毎分最大スピードでボルテックスしながら5分間氷で維持させた。800μl試薬Cを前記溶液に添加し、混合するためにチューブを3〜4回振った。その溶液を4℃で10分間700×gで遠心分離し、そのペレットを粗核分画に使用した。上澄み液を4℃で10分間12,000×gで遠心分離し、原形質分画のために新しいチューブにその上澄み液を移した。そのペレットを500μl試薬Cで洗浄し、分離されたミトコンドリア分画に使用した。各分画はBCAタンパク質分析試薬キット(Pierce)で定量した。サンプルバッファーで沸かした抽出物はSDS−PAGE電気泳動を行って、標準方法によってニトロセルロースに移した。膜を0.05% Tween 20を有するTBS(pH 7.4)内の5%脱脂牛乳でブロットキンし、ミトコンドリア位置マーカーに対する一次抗体である抗−V5(Invitrogen、Carlsbad、CA)、抗−c−Myc(Santa Cruz Biotechnology 、Santa Cruz、CA)または抗−VDAC1(Santa Cruz Biotechnology )で培養した。
カバースリップをHCl、蒸溜水で3回及び100%エタノールで2回洗浄した。その後、乾燥したカバースリップを5μg/ml Poly−L−Lysine(Sigma−Aldrich Corp., MO)で37℃で一夜コーティングした。MCF−7細胞を6ウェルプレートで予めコーティングされたカバースリップの上にシーディングした。その後、一日培養後にその細胞をLipofectamine 2000(Invitrogen、Carlsbad、CA)を使用してpEGFP−HCCR−1及びpEGFP−ApoEで一時的にトランスフェクションした。さらに24−28時間培養し、その細胞を25nM Mito Tracker Orange(Molecular Probes、Eugene、OR)で37℃で15分培養した。細胞を固定する前に2ml PBSで3回洗浄した。その後、カバースリップ上の細胞を4℃で10分間4%のスクロスを含む4%のパラホルムアルデヒドで固定した。細胞を−20℃で1分間100%のメタノールで処理してPBSで3回洗浄した。GFP染色のために、細胞をProLong Gold Antifade試薬(Molecular Probes、Eugene、OR)を使用して固定させた。蛍光イメージをBio−Rad MCR−1024MPレーザースキャニング共焦点顕微鏡(Bio−Rad、Hercules、CA)を使用して分析して得た。
免疫染色化学実験のために、ヒト正常乳房及び乳癌組織のパラフィン切片(5μm厚さ)を使用した。その切片を親和−精製されたポリクローナル抗−HCCR−1抗体で2時間培養した。アミノエチルカボゾル(AEC)を発色原として使用した。免疫染色後の切片をヘマトキシリンで染色した。病理学者がER、PR及びp53に対する最も活性的な染色地域で少なくとも500腫瘍細胞を計数した。ER、PR及びp53に対する陽性染色を核染色として定義した。大体、認められるカットオフ値によって腫瘍細胞の10%陽性染色をER、PR及びp53に対する陽性結果として使用した。HER2免疫化学染色の結果を染色基準によって定義した。HER2に対する陽性染色を膜染色で定義した。原形質染色は陽性と見なさなかった。免疫反応性がないか(スコア0)、不完全であるか、薄い膜染色(スコア1+)を見せる腫瘍細胞を陰性と見なした。HER2は、完全な弱から中間の膜染色(弱い陽性;スコア2+)または完全な強い膜染色(強い陽性;スコア3+)が10%以上の腫瘍細胞で観察される場合、陽性と定義した。
HCCR−1 cDNAまたは954−bp全長ApoE cDNAを使用して、色々なヒト組織でHCCR−1またはApoE発現を調査するために、ノーザンブロット分析を行った。mRNA発現のレベルをベータ−アクチンの発現レベルと比較して、定量化した。
乳癌細胞の増殖期の間、ApoE生成の力学を研究するために、106個の細胞をFBS(10%)を有するDMEM下の75−cm2で8日間繁殖させた。50mlの培地アリコートを8日間、毎24時間ごとに収集してApoE濃度測定時まで−20℃で維持した。ApoE濃度を商業的なキット(MLB ApoE4/Pan−ApoE ELISA kit、MBL Co.,Woburn、MA)を使用して、サンドイッチELISAによって決定した。MBL ApoE4/Pan−ApoE ELISA キット(MBL Co.,Woburn、MA)は、サンドイッチELISAによってヒトApoE4またはPan−ApoEを測定した。その分析には、ApoEに対する親和精製された多重クローン抗体及びApoE4に対するモノクローナル抗体を用いた。
HCCR−1またはApoE−トランスフェクションされた乳癌細胞、pcDNA3.1だけトランスフェクションされた細胞及び野生型細胞を各々3、5及び7日間培養した後収集した。そしてその細胞を溶解して100μg/mlプロテイナーゼKを含有する溶解バッファーで48℃でオーバーナイト処理した。1/5体積の5M NaCl及び同一体積のイソプロピルアルコールを添加してDNAを沈殿させた。そのDNAペレットをTEバッファーに再溶解させ、0.1mg/mlのRNase Aでfor 1h at 37℃で1時間処理した。各サンプルに対して10μg DNAを2%のアガロースゲルで分画し、エチジウムブロマイドで染色して紫外線下で観察した。
トランスジェニックマウスは、Vatten, L.J. & Foss, O.P. Cancer Res 50, 2341−2346(1990)に記載されたように標準前核微細注入法を使用して製造した。微細注入のために、トランスジーンの切片であるHCCR−1をNru I及びXmn IダブルダイジェスチョンによってpcDNA3.1−V5−Hisのベクター骨格なしに分離した。CMV−HCCR−1−bGHの注射された切片を分離し、イレクトロイルージョン及び透析を通じて、分離及び精製して最終濃度2ng/ml DNA注入バッファー(10mM Tris/0.1mM EDTA、pH7.4)で薄めて、C57BL/6N(Charles River Japan)からの単一細胞−ステージ修正胚芽の前核に微細注入した。その後、微細注入で生存した20−25個の注射されたDNA受精卵を注射後2−3時間または翌日に記載のように収容体CD−1(Charles River Japan)マウスの輸卵管の中に移植した。ポテンシャル形質転換ファウンダ動物を3週令で離乳させ、PCRを使用してHCCR−1トランスジーンの存在に対する標準プロトコールで製造されたマウステイルゲノムDNAをスクリーニングして同定し、永続的な系統を開発するために野生型に育つようにした。
体重及びApoE、全体コレステロール、HDL、LDL、トリグリセリド、レプチン及びインスリンの血清濃度は平均±S.Dで示した。t検定及びDunnett’sマルチプル比較をすべての統計分析に使用した。
Claims (7)
- HCCR−1タンパク質を含む乳癌予後マーカーとして使用する、組成物。
- 前記組成物がER、PR、p53遺伝型及びHER2タンパク質からなる群より選択される一つ以上の薬剤をさらに含む、請求項1に記載の組成物。
- 前記HCCR−1タンパク質の配列が配列番号1に記述されている、請求項1に記載の組成物。
- HCCR−1タンパク質を含む、肥満誘導用組成物。
- HCCR−1タンパク質で形質転換された、肥満トランスジェニック非ヒト哺乳動物。
- 前記哺乳動物がマウス、ラット、ウサギ、羊、牛、ヤギ及び豚からなる群より選択される、請求項5に記載の肥満トランスジェニック非ヒト哺乳動物。
- 前記HCCR−1タンパク質の配列が配列番号1に記述されている、請求項4または5に記載の組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060064035A KR100786759B1 (ko) | 2006-07-07 | 2006-07-07 | Hccr-1을 포함하는 유방암 예후 마커 및 비만 유도조성물 |
PCT/KR2007/003293 WO2008004833A1 (en) | 2006-07-07 | 2007-07-06 | Prognostic marker for breast cancer and composition for inducing obesity comprising hccr-1 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2009543044A true JP2009543044A (ja) | 2009-12-03 |
Family
ID=38894757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009517999A Pending JP2009543044A (ja) | 2006-07-07 | 2007-07-06 | Hccr−1を含む乳癌予後マーカー及び肥満誘導組成物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20100205681A1 (ja) |
EP (1) | EP2044442A4 (ja) |
JP (1) | JP2009543044A (ja) |
KR (1) | KR100786759B1 (ja) |
CN (1) | CN101512345A (ja) |
CA (1) | CA2656926A1 (ja) |
WO (1) | WO2008004833A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018514210A (ja) * | 2015-04-27 | 2018-06-07 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | ハイスループットbh3プロファイリング:少量の細胞でのbh3プロファイルのための迅速かつ拡大縮小可能な技術 |
US11215608B2 (en) | 2006-03-31 | 2022-01-04 | Dana-Farber Cancer Institute, Inc. | Methods of determining cellular chemosensitivity |
US11225511B2 (en) | 2002-09-09 | 2022-01-18 | Howard Hughes Medical Institute | BH3 peptides and methods of use thereof |
US11815508B2 (en) | 2012-09-19 | 2023-11-14 | Dana-Farber Cancer Institute, Inc. | Dynamic BH3 profiling |
US11867687B2 (en) | 2013-09-19 | 2024-01-09 | Dana-Farber Cancer Institute, Inc. | Methods of BH3 profiling |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013137686A1 (ko) | 2012-03-15 | 2013-09-19 | 서울대학교 산학협력단 | 그렘린-1에 대한 항체 |
WO2015020242A1 (ko) * | 2013-08-06 | 2015-02-12 | Kim Hyun Kee | 소 간세포암 및 간경변에 잠재되어 있는 간세포암 진단용 조성물 |
CN107576798A (zh) * | 2017-08-30 | 2018-01-12 | 福建师范大学 | Vdac1蛋白在制备乳腺癌术后预后评估试剂盒中的应用、乳腺癌预后评估试剂盒及方法 |
KR102211972B1 (ko) * | 2018-08-02 | 2021-02-04 | 엑소젠 피티이. 엘티디 | 액체생검 다중 암 유전자 바이오마커를 이용한 유방암 조기진단 및 치료 후 모니터링 방법 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003511062A (ja) * | 1999-10-15 | 2003-03-25 | キム、ジン・ウー | ヒト子宮頸部癌1癌原遺伝子およびそれによってコードされるタンパク質 |
JP2004516844A (ja) * | 2001-01-02 | 2004-06-10 | キム、ジン・ウー | ヒト癌原遺伝子を保有する、哺乳動物の癌細胞および形質転換された哺乳動物、ならびにその癌原遺伝子を用いた癌診断用キット |
WO2006016110A1 (en) * | 2004-08-10 | 2006-02-16 | University College Cardiff Consultants Limited | Methods and kit for the prognosis of breast cancer |
WO2006036788A2 (en) * | 2004-09-22 | 2006-04-06 | Tripath Imaging, Inc. | Methods and compositions for evaluating breast cancer prognosis |
-
2006
- 2006-07-07 KR KR1020060064035A patent/KR100786759B1/ko active IP Right Grant
-
2007
- 2007-07-06 CN CNA2007800334744A patent/CN101512345A/zh active Pending
- 2007-07-06 WO PCT/KR2007/003293 patent/WO2008004833A1/en active Application Filing
- 2007-07-06 US US12/309,102 patent/US20100205681A1/en not_active Abandoned
- 2007-07-06 CA CA002656926A patent/CA2656926A1/en not_active Abandoned
- 2007-07-06 JP JP2009517999A patent/JP2009543044A/ja active Pending
- 2007-07-06 EP EP07793194A patent/EP2044442A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003511062A (ja) * | 1999-10-15 | 2003-03-25 | キム、ジン・ウー | ヒト子宮頸部癌1癌原遺伝子およびそれによってコードされるタンパク質 |
JP2004516844A (ja) * | 2001-01-02 | 2004-06-10 | キム、ジン・ウー | ヒト癌原遺伝子を保有する、哺乳動物の癌細胞および形質転換された哺乳動物、ならびにその癌原遺伝子を用いた癌診断用キット |
WO2006016110A1 (en) * | 2004-08-10 | 2006-02-16 | University College Cardiff Consultants Limited | Methods and kit for the prognosis of breast cancer |
WO2006036788A2 (en) * | 2004-09-22 | 2006-04-06 | Tripath Imaging, Inc. | Methods and compositions for evaluating breast cancer prognosis |
Non-Patent Citations (1)
Title |
---|
JPN6012007283; Sang Seol Jung et al.: 'The HCCR Oncoprptein as a Biomarker for Human Breast Cancer' Clin Cancer Res Vol.11, No.21, 20051101, 7700-7708, American Association for Cancer Research * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11225511B2 (en) | 2002-09-09 | 2022-01-18 | Howard Hughes Medical Institute | BH3 peptides and methods of use thereof |
US11215608B2 (en) | 2006-03-31 | 2022-01-04 | Dana-Farber Cancer Institute, Inc. | Methods of determining cellular chemosensitivity |
US11815508B2 (en) | 2012-09-19 | 2023-11-14 | Dana-Farber Cancer Institute, Inc. | Dynamic BH3 profiling |
US11867687B2 (en) | 2013-09-19 | 2024-01-09 | Dana-Farber Cancer Institute, Inc. | Methods of BH3 profiling |
JP2018514210A (ja) * | 2015-04-27 | 2018-06-07 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | ハイスループットbh3プロファイリング:少量の細胞でのbh3プロファイルのための迅速かつ拡大縮小可能な技術 |
US10761086B2 (en) | 2015-04-27 | 2020-09-01 | Dana-Farber Cancer Institute, Inc. | High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells |
US11867688B2 (en) | 2015-04-27 | 2024-01-09 | Dana-Farber Cancer Institute, Inc. | High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells |
Also Published As
Publication number | Publication date |
---|---|
US20100205681A1 (en) | 2010-08-12 |
WO2008004833A1 (en) | 2008-01-10 |
EP2044442A4 (en) | 2010-04-28 |
CA2656926A1 (en) | 2008-01-10 |
CN101512345A (zh) | 2009-08-19 |
KR100786759B1 (ko) | 2007-12-18 |
EP2044442A1 (en) | 2009-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009543044A (ja) | Hccr−1を含む乳癌予後マーカー及び肥満誘導組成物 | |
Dunn et al. | A novel role of myosin VI in human prostate cancer | |
Ho et al. | Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation | |
Merritt et al. | Suprabasal desmoglein 3 expression in the epidermis of transgenic mice results in hyperproliferation and abnormal differentiation | |
Yang et al. | Intestinal inflammation reduces expression of DRA, a transporter responsible for congenital chloride diarrhea | |
Gopalakrishnan et al. | Rho GTPase signaling regulates tight junction assembly and protects tight junctions during ATP depletion | |
Engevik et al. | Loss of MYO5B leads to reductions in Na+ Absorption with maintenance of CFTR-Dependent Cl–Secretion in enterocytes | |
La Fontaine et al. | Effect of the toxic milk mutation (tx) on the function and intracellular localization of Wnd, the murine homologue of the Wilson copper ATPase | |
Mandal et al. | Spatial and temporal expression of MFRP and its interaction with CTRP5 | |
Mas et al. | Overexpression of the truncated form of High Mobility Group A proteins (HMGA2) in human myometrial cells induces leiomyoma-like tissue formation | |
Puzianowska-Kuznicka et al. | Expression of thyroid hormone receptors is disturbed in human renal clear cell carcinoma | |
Fini et al. | Membrane-associated mucins of the ocular surface: New genes, new protein functions and new biological roles in human and mouse | |
Luu et al. | Human intestinal MUC17 mucin augments intestinal cell restitution and enhances healing of experimental colitis | |
KR102378462B1 (ko) | 비알코올성 간질환 동물 모델 및 비알코올성 간질환의 진단, 예방 또는 치료용 조성물 | |
US20210190799A1 (en) | Method for diagnosing liver diseases and method for screening therapeutic agent for liver diseases using changes in expression of tm4sf5 protein | |
Roelofsen et al. | Glutathione S-conjugate transport in hepatocytes entering the cell cycle is preserved by a switch in expression from the apical MRP2 to the basolateral MRP1 transporting protein | |
Stabile et al. | Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer | |
Ohta et al. | Sex-dependent effects of chromogranin B P413L allelic variant as disease modifier in amyotrophic lateral sclerosis | |
Li et al. | Epithelial splicing regulatory protein 1 inhibits the invasion and metastasis of lung adenocarcinoma | |
JP4718556B2 (ja) | 癌の診断と治療のためのaimp2dx2の用途 | |
Ling et al. | Suppression of non-small cell lung cancer proliferation and tumorigenicity by DENND2D | |
Fischer et al. | Impaired tight junction sealing and precocious involution in mammary glands of PKN1 transgenic mice | |
Wang et al. | High-fat diet-induced hyperinsulinemia promotes the development of prostate adenocarcinoma in prostate-specific Pten−/− mice | |
Zhai et al. | HoxB2 binds mutant SOD1 and is altered in transgenic model of ALS | |
Jakhotia et al. | Obesity-related glomerulopathy is associated with elevated WT1 expression in podocytes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100706 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120126 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120214 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120514 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120521 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121016 |